Some studies have shown that in vivo administration of PPAR-γ agonist substances can stimulate adipocyte differentiation and fatty acid oxidation, promote weight loss, and reduce adipocytes and adipose tissue, thus achieving an anti-obesity effect [20,21]. This evidence concerns the gene PPARG and obesity due to melanocortin 4 receptor deficiency.